Chemify Raises Over $50 Million Series B to Scale Its Digital Chemistry Platform Globally
The deep-tech chemistry startup Chemify has raised more than US $50 million in its latest Series B funding round, marking a major inflection point in its ambition to digitise molecular design and manufacturing. The oversubscribed round was co-led by Wing Venture Capital and Insight Partners, with participation from a syndicate of venture-backed investors including 8VC, Triatomic Capital, BlueYard Capital, Rockspring Ventures and Eos Venture Partners.
Chemify, headquartered in Glasgow and spun out of the University of Glasgow, is building a platform it calls “Chemputation” that combines artificial intelligence, robotics and a massive library of validated chemical reactions to make molecular design programmable. The company also recently launched its first “Chemifarm” facility—an automated molecular-production hub that converts digital chemical code into actual compounds. With this new capital injection, Chemify plans to scale those facilities globally—including a planned site in Silicon Valley—and invite pharmaceutical, biotech and materials-science partners to use its infrastructure for rapid molecule creation.
The funding arrives at a time when the pressure on drug-discovery and advanced-materials industries is growing: companies face rising complexity, slower pipelines and high costs for synthesising novel molecules. Chemify’s proposition is aimed squarely at that gap, promising on-demand molecule design and synthesis at a speed and scale previously inaccessible. The round builds on earlier raises—including a Series A in 2023 of approximately US $43 million led by Triatomic Capital—which helped Chemify refine its platform and establish early infrastructure.
Investors believe the company’s model—bringing together deep domain chemistry with advanced automation and AI—is distinct and capable of shifting how molecules are discovered and manufactured. Wing Venture Capital, as co-lead, emphasised that Chemify’s technology “transforms chemical synthesis from an art to a programmable science.” Insight Partners highlighted the market potential and the company’s leadership in digitising chemistry as key to enabling faster, better and more cost-effective innovation in complex molecules.
With the funds secured, Chemify is set to expand its engineering, product and manufacturing teams; build out its network of digital chemistry hubs; strengthen its collaborations with pharmaceutical and materials companies; and accelerate the commercial rollout of its platform. One immediate priority is operationalising its first Chemifarm fully and replicating the model in new regions, thereby shortening the timeline from digital design to physical molecule by orders of magnitude. The company also signals that its system targets not just drug discovery but catalysis, electronics-materials development, advanced polymers and other high-value molecular markets.
Despite the enthusiasm and financial backing, Chemify will need to execute effectively across a number of demanding fronts. Scaling robotics and automation reliably, maintaining large curated reaction datasets, integrating with partners’ workflows, demonstrating commercial value and meeting regulatory or supply-chain challenges will all be part of its climb. However, with this new raise and a strong investor group behind it, the company appears to have the capital and support to meet those ambitions.
In summary, Chemify’s US $50 million+ Series B round—co-led by Wing Venture Capital and Insight Partners and supported by 8VC, Triatomic Capital, BlueYard Capital, Rockspring Ventures and Eos Venture Partners—marks a pivotal milestone in the company’s mission to digitise chemistry. By scaling its Chemputation platform and Chemifarm facilities globally, the startup is aiming to become the programmable backbone of molecule creation and manufacturing across pharma, biotech and advanced-materials sectors.
